Merck's Clesrovimab (MK-1654) shows positive results in Phase 2b/3 trial for RSV prevention in infants.

Merck announces positive Phase 2b/3 trial results for RSV preventative monoclonal antibody, Clesrovimab (MK-1654), reducing medically attended lower respiratory infections in infants. The highly contagious RSV is a leading cause of infant hospitalization and has a significant global burden. Merck plans to present detailed findings and file data with global regulators, aiming to provide a new option for RSV impact on infants and families.

July 23, 2024
3 Articles